Sartar received Orphan Drug Designation from the FDA

We are delighted to announce that Sartar Therapeutics received Orphan Drug Designation for GIST from the U.S. Food & Drug administration (FDA). This is a great addition to our Orphan Drug Designation in EU granted by the European Medicines Agency (EMA) earlier this year.

See Orphan Drug Designation in FDA’s database.